Spherix is a biotechnology company seeking to develop small-molecule anti-cancer therapeutics. Co. owns the rights to patented technology from universities and researchers and it is in the process of developing therapeutic drugs through partnerships with educational institutions. Co.'s pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Co.'s AML and ALL compounds are targeted therapeutics designed to overcome various resistance mechanisms observed with the existing standard of care. DHA-dFdC, Co.'s pancreatic drug, is a compound poised to become the chemotherapy treatment for pancreatic cancer. We show 2 historical shares outstanding datapoints in our AIKI shares outstanding history coverage, used to compute AIKI market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AIKI market cap history over the course of time is important for investors
interested in comparing AIKI's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AIKI versus a peer is one thing; comparing
AIKI market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AIKI can fluctuate over the course of history.
With this page we aim to empower investors researching AIKI by allowing them to research the AIKI market cap history. |
Video: The Importance of Market Cap
